All In Biotech

NDA 022408 · Cipher

Natroba

Spinosad · Topical · Pediculicide

Novel

Last checked: Nov 20, 2026Latest source record: Apr 28, 2021 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2011

Jan 18, 2011

Approved uses

3

Original approval plus efficacy supplements

Registered trials

13

4 Phase 3, 0 recruiting

FAERS reports

47

13 serious, 2 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Mar 4, 2026.

Spinosad Topical Suspension is a pediculicide indicated for the topical treatment of head lice infestations in adult and pediatric patients 6 months of age and older. ( 1.1 ) Spinosad Topical Suspension is a scabicide indicated for the topical treatment of scabies infestations in adult and pediatric patients 4 years of age and older. ( 1.2 ) 1.1 Head Lice Infestations Spinosad Topical Suspension is indicated for the topical treatment of head lice infestations in adult and pediatric patients 6 months of age and older. Adjunctive Measures for Head Lice Infestations Spinosad Topical Suspension should be used in the context of an overall lice management program: Wash in hot water or dry-clean all recently worn clothing, hats, used bedding and towels. Wash personal care items such as combs, brushes and hair clips in hot water. A fine-tooth comb or special nit comb may be used to remove dead lice and nits. 1.2 Scabies Infestations Spinosad Topical Suspension is indicated for the topical treatment of scabies infestations in adult and pediatric patients 4 years of age and older. Adjunctive Measures for Scabies Infestations Wash in hot water or dry-clean any bedding, clothing and towels used by anyone having scabies.

Mechanism: Spinosad causes neuronal excitation in insects. After periods of hyperexcitation, lice and mites become paralyzed and die.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • NATROBA · SPINOSAD 0.9% · SUSPENSION, TOPICAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Spinosad" as an intervention, any sponsor and status, largest first.

All 13 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective15
  • pruritus7
  • alopecia5
  • rash4
  • condition aggravated3
  • erythema3
  • abdominal pain upper2
  • burning sensation2
  • death2
  • headache2
  • lice infestation2
  • paraesthesia2

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20113
20128
20131
20142
20161
20173
20182
20193
20204
20212
20221
20233
20243
20257
20264

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Natroba (Spinosad)

2024 spending

$161K

Beneficiaries

440

580 claims

Per beneficiary

$367

$2.22 per unit

View as table
YearSpending
2020$82,555
2021$51,021
2022$98,871
2023$131,063
2024$161,297

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 26 on PubMed

Sponsor: Cipher

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.